
Exhibit 9



30 August 2001

Dr I Hatton Heath House 28 West Street Reigate Surrey RH2 9BX



New Frontiers Science Park Third Avenue Harlow Essex CM19 SAW

Tel. +44 (0) 1279 622000 Fax. +44 (0) 1279 644100 www.gsk.com

Dear Ian

I understand from my colleague Sarah Doe that you disagree with the inventorship for our patent case P32162 (US09/807275) and therefore have declined to sign the US Declaration. As you are aware, you have been named as inventor along with Neil Pearson. I hope the following explanation of the inventorship determination will help to reassure you that the determination was accurate and you will feel able to comply with your employment contract and sign the form as requested.

The basic scope of quinicine compounds for which you were a co-inventor was included in the original UK patent application case no P30388 filed in 1992 (copy enclosed). This related exclusively to quinoline derivatives.

A search of the R&D archive revealed only one document under your name relating to proposals for further chemistry for the compounds. This was the Quinicine Research Proposal of October 1992 (copy enclosed). In this document are the following proposals:

- varying the 2-substituent on the quinoline
- varying the piperidine N substituent
- varying the length of the CH2 chain linking the quinoline to the piperidine
- replacement of the 3-ethyl substituent on the piperidine with H or methyl
- piperidine replacements: pyrrolidines and bridged piperidines
- quinoline replacements: pyrimidine and quinazoline

Only one aspect of the above proposals is relevant to the scope of the present case P32162, namely the replacement of quinoline by quinazoline. In my view it is this proposal which forms the basis of your inventive contribution.

imithKline Beecham Pharmaceuticals s e business name ul SmithKlina Beacham plo

Registered in England & Wales

No. 2337959

Registered Office New Horizons Court, Brentford, Middletex TW8 9CI

ة 200£ طوي

However the case P32162 as filed includes a number of additional aspects of scope which were not forshadowed in the above proposals, including but not limited to:

- bicyclic heteroaromatic rings other than quinazoline eg naphthyridine and cinnoline
- inclusion of NR11, O and S(O)x in the definitions of the linker groups A and B

It is these aspects of the scope, among others, which were contributed entirely by Neil Pearson and for that reason I have named him as a co inventor.

If you feel it necessary to discuss this matter further I would suggest a meeting between you, me and Peter O'Hanlon in order for you to explain your point of view. Please call me on 01279 644401 to arrange a suitable date and venue. We could arrange to meet at New Horizons Court or Tonbridge if that would be convenient for you. However I would point out that the final legal determination of inventorship will remain with me.

I enclose a further copy of the PCT published patent specification for your reference.

We would appreciate your returning the signed Declaration to us by 30 September. We will of course reimburse any reasonable costs incurred in reviewing and signing the form.

Thank you in advance for your cooperation.

Yours sincerely

Jill B Valentine (Mrs)

TELOUZZ

Encs